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Combining transcranial magnetic stimulation (TMS) and electroencephalography (EEG) constitutes a powerful tool to directly assess 
human cortical excitability and connectivity. TMS of the primary motor cortex elicits a sequence of TMS-evoked EEG potentials (TEPs). 
It is thought that inhibitory neurotransmission through GABA-A receptors (GABAAR) modulates early TEPs (<50 ms after TMS), 
whereas GABA-B receptors (GABABR) play a role for later TEPs (at ~ 100 ms after TMS). However, the physiological underpinnings of 
TEPs have not been clearly elucidated yet. Here, we studied the role of GABAA/B-ergic neurotransmission for TEPs in healthy subjects 
using a pharmaco-TMS-EEG approach. In Experiment 1, we tested the effects of a single oral dose of alprazolam (a classical benzodiaz-
epine acting as allosteric-positive modulator at a l , al, a3, and a5 subunit-containing GABAARs) and Zolpidem (a positive modulator 
mainly at the a l GABAAR) in a double-blind, placebo-controlled, crossover study. In Experiment 2, we tested the influence of baclofen (a 
GABABR agonist) and diazepam (a classical benzodiazepine) versus placebo on TEPs. Alprazolam and diazepam increased the amplitude 
of the negative potential at 45 ms after stimulation (N45) and decreased the negative component at 100 ms (N100), whereas Zolpidem 
increased the N45 only. In contrast, baclofen specifically increased the N100 amplitude. These results provide strong evidence that the 
N45 represents activity of al-subunit-containing GABAARs, whereas the N100 represents activity of GABABRs. Findings open a novel 
window of opportunity to study alteration of GABAA-/GABAB-related inhibition in disorders, such as epilepsy or schizophrenia. 
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Introduction 
Transcranial magnetic stimulation (TMS) is a noninvasive brain 
stimulation method that allows to study human cortical function 
in vivo (Hallett, 2007). However, the potential of TMS as a stand-
alone technique is limited. This potential can be enhanced by 
combining TMS with simultaneous registration of electroen-
cephalography (EEG), thus providing direct information about 
cortical excitability and connectivity with reasonable spatial and 
excellent time resolution (Rogasch and Fitzgerald, 2013). A single 
TMS pulse delivered over the primary motor cortex (Ml) results 
in a sequence of positive and negative EEG deflections. These 
TMS-evoked cortical potentials (TEPs) last for up to 300 ms in 
both the vicinity of the stimulation as well as in remote inter-
connected brain areas (Ilmoniemi et a l , 1997; Bonato et al., 
2006; Lioumis et a l , 2009). TMS-EEG recordings have pro-
vided important insights into cortical processing both in 
health (Massimini et a l , 2005; Ferrarelli et a l , 2010) and dis-
ease (Rosanova et al., 2012; Ragazzoni et a l , 2013). However, 
the neurophysiological underpinnings of TEPs have not been 
clearly elucidated yet. 
Animal studies show that electrical stimulation of a cortical 
area provokes an initial, brief excitation followed by two phases of 
inhibition (Connors et al, 1988). The first inhibition (fast IPSP 
[flPSP]) occurs at short latencies <50 ms and is linked to activa-
tion of GABA-A receptors (GABAARs). The second inhibition 
(slow IPSP [sIPSP]) has a delayed onset, is long-lasting (50-200 
ms), and is generated by an increase in potassium conductance 
via activation of metabotropic GABA-B receptors (GABABRs) 
(Connors et al, 1988; Deisz, 1999). Based on these findings, it was 
hypothesized that activation of GABAARs contributes to the TEP 
at ~45 ms after TMS over Ml (N45), whereas activation of 
GABABRs is involved in the negative deflection at ~ 100 ms after 
TMS (N100) (Nikul ineta l . ,2003;Ferrer ie ta l . ,2011;Bruckmann 
et a l , 2012; Rogasch and Fitzgerald, 2013; Farzan et a l , 2013). 
Here, we tested these hypotheses in healthy human subjects 
by conducting two separate double-blind, placebo-controlled 
pharmaco-TMS-EEG studies. In Experiment 1, we investigated the 
acute effects of alprazolam, a classical benzodiazepine and 
allosteric-positive modulator of a l , al, oñ, and a5 subunits of 
the GABAARs, and Zolpidem, which mainly binds at a l - subun i t -
containing GABAARs, on TEP amplitudes. W e aimed to study 
the role of different a-subunit-containing GABAARs as they un-
derlie different physiological functions (Mohler et a l , 2002), and 
differentially underlie the pathophysiology of epilepsy (Cossette 
et a l , 2002), schizophrenia (Uhlhaas and Singer, 2012), or devel-
opmental cortical plasticity (Fagiolini et a l , 2004). In Experiment 
2, we studied the acute effects of baclofen, a specific GABABR 
agonist, and diazepam, a classical benzodiazepine, on TEP am-
plitudes. Alprazolam and diazepam increased the N45 and de-
creased the N100 amplitude, whereas Zolpidem increased the 
N45 amplitude only. In contrast, baclofen specifically increased 
the N100 amplitude without affecting earlier TEPs. These data 
suggest that the N45 represents activity of a l - subuni t -conta in ing 
GABAARs, whereas the N100 represents activity of GABABRs. 
These TMS-EEG findings can help to further characterize func-
tion of the GABAergic inhibitory system in health and disease. 
Materials and Methods 
Subjects 
Twenty-two male subjects 21-32 years of age (mean age, 25.0 ± 2.5 
years) and 19 male subjects 22-32 years of age (26.4 ± 3.5 years) partic-
ipated after giving written informed consent in Experiments 1 and 2, 
respectively. Female participants were excluded in both studies because 
of menstrual cycle-related effects on cortical excitability, which can be a 
potential confound in TMS studies (Smith et al., 1999). All subjects were 
right-handed according to the Edinburgh Handedness Inventory (later-
ality score >75%) (Oldfield, 1971). Subjects underwent a physical exam-
ination before each experiment and were screened for contraindications 
to TMS (Rossi et al., 2009). Exclusion criteria included the presence of a 
history of neurological or psychiatric disease, use of CNS active drugs, 
abuse of any drugs (including nicotine and alcohol), or contraindica-
tions to the study medications (alprazolam, Zolpidem, diazepam and 
baclofen). 
Experiments were approved by the Federal Institute for Drugs and 
Medical Devices (Bundesinstitut für Arzneimittel und Medizin-
produkte), and by the local Ethics Committees of the Medical Faculty of 
Goethe-University Frankfurt (Experiment 1) and the Medical Faculty of 
Eberhard-Karls-University Tubingen (Experiment 2). 
Experimental design 
Experiment 1. The first experiment was designed to investigate the role 
of GABAA-ergic neurotransmission on TMS-evoked EEG recordings. 
To address this question, we used a pseudo-randomized, placebo-
controlled, double-blinded crossover study to assess the acute effects of a 
single oral dose of alprazolam versus Zolpidem on TEPs. Alprazolam is a 
classical benzodiazepine and allosteric-positive modulator of a l , a2, a3, 
and a5 subunit-containing GABAARs, whereas Zolpidem is a short-
acting nonbenzodiazepine hypnotic that preferentially binds to a l 
subunit-containing GABAARs. Subjects participated in three experi-
mental sessions at least 1 week apart. After baseline measurements, 
subjects received a single oral dose of alprazolam (1 mg, Alprazolam-
ratiopharm, ratiopharm), Zolpidem (10 mg, Zolpidem-ratiopharm, 
ratiopharm), or placebo (P-Tabletten Lichtenstein) (Fig. 1). The order of 
drug allocation was pseudo-randomized and balanced across subjects. 
Dosages of alprazolam and Zolpidem were chosen because they are effec-
tive standard daily doses in the treatment of patients with anxiety or sleep 
disorders, respectively, and according to previously shown sedative ef-
fects by these drugs as indexed by a significant slowing of the saccadic 
peak velocity (SPV) (Blom et al., 1990; de Haas et al., 2010). 
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Figure 1 . Timeline of experiments. Peak velocity of visually guided saccades (Saccades) and 
EEG responses evoked by single-pulse TMS overthe dominant (left) primary motor cortex (TMS-
EEG) were measured before and 90 min after intake of a single oral dose of alprazolam (1 mg), 
Zolpidem (10 mg), or placebo (Experiment 1), or diazepam (20 mg), baclofen (50 mg), or 
placebo (Experiment 2). 
Postdrug measurements were performed 90 min after drug intake 
according to drug pharmacokinetics with plasma levels peaking at ~ 1.5 h 
after oral intake (Greenblatt and Wright, 1993; Salva and Costa, 1995) 
and in line with previous reports, where TMS measures of motor cortical 
excitability were significantly altered at this time point (Greenblatt and 
Wright, 1993; Salva and Costa, 1995; DiLazzaroetal., 2006; DiLazzaroet 
al., 2007). 
Experiment 2. The second experiment aimed at assessing the role of 
GABAB-ergic neurotransmission for TEPs. To this end, subjects took a 
single oral dose of baclofen (50 mg Lioresal, Novartis Pharma), diazepam 
(20 mg Diazepam-ratiopharm, ratiopharm), or placebo (P-Tabletten 
Lichtenstein). Baclofen is a specific GABABR agonist, whereas diazepam 
is a classical benzodiazepine binding at a l , a2, a3, and a5 subunit-
containing GABAARs. Diazepam was included into Experiment 2 to 
study the specificity of baclofen-mediated modulation of TEPs (see be-
low). Given its similar pharmacological profile with respect to alprazo-
lam (Experiment 1), it also allowed validation of GABAAR-mediated 
modulation of TEPs. 
As for Experiment 1, subjects participated in three pseudo-
randomized experimental sessions, at least 1 week apart, where the effects 
of the drugs on TEPs were evaluated 90 min after baseline measurements 
(Fig. 1). Drug doses and time point of postdrug measurements were 
chosen according to previous experiments that reported a significant 
modulation of TMS parameters for cortical inhibition 1.5 h after drug 
intake (Müller-Dahlhaus et al., 2008) and in line with the pharmacoki-
netics of the two study medications (Shader et al., 1984; McDonnell et al., 
2006). 
SPV measurements 
Visually guided SPV is a biomarker of sedation mediated through a l 
subunit-containing GABAARs (de Visser et al., 2003; de Haas et al., 2009, 
2010). SPV was measured at baseline and after drug intake (Fig. 1). 
Subjects sat in front of a screen (eyes to screen distance, 67.5 cm) and 
were instructed to make visually guided saccades in response to a white 
dot (subtending an angle of view of Io) on a black screen while the head 
was maintained in straight position. The dot jumped at random intertrial 
intervals of 2-3 s (to prevent anticipation of the next event) horizontally 
from one lateral edge to the opposite edge of the screen, subtending an 
angle of view of 40°. Both before and after drug intake, 50 trials were 
presented. Saccade recordings were obtained by electronystagmography 
(ENG) using surface electrodes placed at the outer canthus of each eye. 
The ENG raw signals were amplified and bandpass filtered (0.5-70 Hz; 
Digitimer D360), digitized at an A/D rate of 10 kHz per channel (CED 
Micro 1401; Cambridge Electronic Design), and stored in a laboratory 
computer for online visual display and later offline analysis using cus-
tomized data collection and conditional averaging software. ENG data 
were then exported into MATLAB (version 2008b; MathWorks), and 
in-house-written software was used for manual identification of saccade 
onset and offset (Velázquez-Pérez et al., 2004). SPV (in °/s) was obtained 
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Figure 2. Visually guided saccade peak velocity (SPV). SPV was measured before (Pre, black bars) and 90 min after (Post, white 
bars) intake of a single oral dose of 1 mg alprazolam, 10 mg Zolpidem, or placebo (Experiment '\,A)I or 20 mg diazepam, 50 mg 
baclofen, or placebo (Experiment 2, B). A, Data are means from 20 subjects. B, Data are means from 15 subjects. Error bars 
indicate ± SEM. *Significant differences predrug versus postdrug [p < 0.05). 
through third-order polynomial fits of the ENG raw signal. Conditional 
SPV averages were calculated for leftward and rightward saccades, and a 
grand mean was calculated for each individual, session, and measure-
ment (predrug/postdrug intake). 
TMS 
Focal TMS of the hand area of left primary motor cortex (Ml) was 
performed with a figure-of-eight coil (external diameter of each wing, 90 
mm) connected to a Magstim 200 2 magnetic stimulator (Magstim) with 
a monophasic current waveform. The optimal coil position over the 
hand area of left Ml for eliciting MEPs in the right abductor pollicis 
brevis muscle (APB) was determined as the site where TMS at a slightly 
suprathreshold intensity consistently produced the largest MEPs. MEP 
recordings were obtained by surface EMG, using Ag-AgCl cup electrodes 
in a belly-tendon montage. The EMG raw signal was amplified and 
bandpass filtered (20 Hz to 2 kHz; D360 amplifier, Digitimer) and digi-
tized at an A/D rate of 10 kHz per channel (CED Micro 1401; Cambridge 
Electronic Design). The coil was held tangential to the scalp with the 
handle pointing backwards and 45 degrees away from the midline. This 
orientation induces a lateral-posterior to medial-anterior current in 
the brain, activating the corticospinal system preferentially trans-
synaptically via horizontal corticocortical connections (Di Lazzaro et al., 
2008). Resting motor threshold (RMT) was determined using the relative 
frequency method (Groppa et al., 2012) and was defined as the minimum 
intensity that was sufficient to elicit an MEP of >50 /J,V peak-to-peak 
amplitude in at least five often subsequent trials. The position of the APB 
hotspot was marked with a felt pen on the EEG cap to ensure constant coil 
placement throughout the experiment. 
High-density EEG recordings during TMS 
TMS-evoked EEG potentials were recorded using a TMS-compatible 
EEG system (BrainAmp DC, BrainProducts), which prevents EEG am-
plifier saturation and allows continuous data recording during TMS. The 
EEG signal was digitized at a sampling frequency of 5 kHz and continu-
ously recorded by 62 electrodes mounted on an elastic cap according to 
the standard layout (BrainCap-Fast'n Easy 64Ch, Brain Products). Hor-
izontal eye movements were recorded by placing an electrode outside the 
outer canthus of the eye while an electrode placed below the right eye 
recorded vertical eye movements and blinks. The impedance of all elec-
trodes was kept < 5 kfí throughout the experiment. 
During TMS-EEG recordings, subjects were seated on a comfortable 
reclining chair and asked to stay awake with eyes open. A masking noise 
was applied by earphones to avoid contamination of the EEG signal by 
auditory potentials evoked by the click associated with current discharge 
through the TMS coil (Massimini et al., 2005). At baseline and at 90 min 
after drug intake, 150 TMS pulses (Experiment 1) or 125 TMS pulses 
(Experiment 2) each were applied over the left Ml APB hotspot at an 
intensity of 100% RMT. Thus, no or only liminal MEPs were elicited 
during TMS-EEG recordings. Therefore, the TEPs were not contami-
nated by somatosensory afferent signals from muscle twitches. The in-
terstimulus interval between TMS pulses was, on average, 5 s (random 
intertrial interval variation of 25% to reduce anticipation of the next 
trial). 
Data processing and TEP analysis 
EEG data preprocessing and TEP analysis were 
performed using the Fieldtrip open source 
MATLAB toolbox (www.ru.nl/fcdonders/ 
fieldtrip/) (Oostenveld et al., 2011). The EEG 
signal was first rereferenced to the linked mas-
toids (channels TP9 and TP10) and down-
sampled to 1 kHz. EEG trials were segmented 
from continuously recorded EEG time series 
from —500 ms before to 500 ms after TMS 
pulses. The TMS artifact was removed by ap-
plying a linear interpolation for 10 ms before 
and after the TMS pulse (Thut et al., 2011). 
Thereafter, each trial was linearly detrended 
and bandpass filtered between 2 and 80 Hz. A 
50 Hz notch filter was applied to reduce line 
noise contamination. EEG trials were visually 
scrutinized, and trials containing artifacts resulting from, for example, 
eye movements or muscle activation, were eliminated. The data from 2 
subjects in Experiment 1 and 4 subjects in Experiment 2 had to be ex-
cluded from final analysis because of excessive artifact contamination of 
the EEG traces. 
Artifact-free EEG trials for Experiment 1 (averaged number of trials 
across subjects in before and after alprazolam: 126 ± 5 and 119 ± 4; 
Zolpidem: 125 ± 3 and 109 ± 3; placebo: 123 ± 4 and 128 ± 3) and 
Experiment 2 (averaged number of trials across subjects in before and 
after diazepam: 107 ± 3 and 99 ± 3; baclofen: 109 ± 3 and 108 ± 3; 
placebo: 104 ± 3 and 107 ± 4) were baseline corrected by subtracting the 
mean amplitude during an interval between —500 ms and —100 ms 
before the TMS onset. TEPs were then calculated by averaging the EEG 
signal over all retained trials for each channel. To smooth the TEP, we 
used data filtered between 1 and 45 Hz. We considered five TEP compo-
nents (P, positive deflection; N, negative deflection), which were the 
most reproducible: P25 (time window of interest [TOI]: 20-30 ms),N45 
(35-60 ms), P70 (60-80 ms), N100 (85-140 ms), and P180 (150-230 
ms) [Experiment 1]; P25 (20-37 ms), N45 (40-60ms), P70 (65-85 ms), 
N100 (88-150 ms), and P180 (150-230 ms) [Experiment 2], in accor-
dance with the literature (Lioumis et al., 2009) (see Fig. 3). TOIs were 
chosen on the basis of grand averaged TEPs, which were slightly different 
between Experiments 1 and 2 because of intersubject variability of peak 
latencies of TEP components (Lioumis et al., 2009) and were kept iden-
tical for the analysis of each predrug and postdrug condition. The ampli-
tude of each TEP component (measured as peak to baseline) was 
evaluated before and after drug administration in the specified TOIs. 
It has been recently proposed that spontaneous and drug-induced 
changes of a oscillations can affect somatosensory-evoked potentials 
(Nikulin et al., 2007; Supp et al., 2011). To rule out an effect of drug-
induced changes of neural oscillations on TEPs, a Morlet-wavelet convo-
lution of a width of 5 cycles per wavelet was used to analyze the power 
spectra of the EEG signal at baseline (i.e., —500 ms to —100 ms before 
TMS) in the 0 (4 -8 Hz), a (8-12 Hz), |3 (13-30 Hz), and y (30-50 Hz) 
frequency bands in Experiment 1 and 2 separately. We then extracted the 
average power values for each spectral band as well as the TEP amplitudes 
for each subject before and after drug administration in the channels that 
showed a drug-induced change in TEP amplitude (see Results). Spear-
man correlation analyses were run between the TEP amplitude change 
(amplitude postdrug — amplitude predrug) and the baseline power 
modulation (power postdrug — power predrug) in the different drug 
conditions. 
Statistics 
To evaluate drug effects on SPV, a repeated-measures ANOVA was per-
formed independently for Experiments 1 and 2, with drug (3 levels: 
alprazolam, Zolpidem, placebo [Experiment 1]; baclofen, diazepam, pla-
cebo [Experiment 2]) and time (2 levels: predrug, postdrug) as within-
subject factors. 
To assess whether RMT measurements were similar and reproducible 
in the three predrug conditions, one-way repeated-measures ANOVAs 
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Figure 3. TEPs before drug intake. Grand-average TEPs (over all electrodes and artifact-free trials) induced by left Ml TMS before intake of alprazolam (red), Zolpidem (black), or placebo (blue) 
(Experi ment 1, A), and diazepam (red), baclofen (black), or placebo (blue) (Experiment 2, B). The time of TMS equals Oms. The shaded gray bar represents the pa it of the EEG trace ( ± 10 ms) that 
was linearly interpolated to remove the TMS-induced artifact. TEP components are labeled according to their polarity and approximate latency. Bottom line indicates topographical distributions of 
surface voltages for the most pronounced TEP components (P25, N45, P70, N100, P180; grand-average across predrug measurements in the three drug conditions) for Experiment 1 [A) and 
Experiment 2 (B). Maps are scaled and color-coded individually according to their respective maximum (red) and minimum (blue). 
with factor drug condition (3 levels: Experiment 1: alprazolam, Zolpi-
dem, placebo; Experiment 2: diazepam, baclofen, placebo) were used. 
To analyze drug-induced TEP amplitude modulations, multiple de-
pendent sample t tests (predrug vs postdrug intake) were applied on the 
level of individual electrodes within each drug condition and each TOI 
separately. To correct for multiple comparisons (i.e., electrodes, time 
points within TOIs), we conducted a cluster based permutation anal-
ysis (Maris and Oostenveld, 2007) as implemented in FieldTrip 
(http://fieldtrip.fcdonders.nl/). That is, a paired t test comparing the 
predrug versus postdrug condition was conducted for each electrode at 
each time bin within the five different TOIs. t values exceeding an a priori 
threshold of p < 0.01 were clustered based on adjacent time bins and 
neighboring electrodes. Cluster-level statistics were calculated by taking 
the sum of the t values within every cluster. The statistical comparisons 
were done with respect to the maximum values of summed t values. By 
means of a permutation test (i.e., randomizing data across predrug and 
postdrug conditions and rerunning the statistical test 1500 times), we 
obtained a reference distribution of the maximum of summed cluster f 
values to evaluate the statistic of the actual data. Clusters in the original 
dataset were considered to be significant at an a level of 5% if < 5 % of the 
permutations used to construct the reference distribution yielded a max-
imum cluster-level statistic larger than the cluster-level value observed in 
the original data. 
The reported p values are further Bonferroni-corrected for TOIs (« = 
5) and predrug and postdrug conditions (« = 2), which is reflected by a 
corrected a value = 0.05/10. 
All data are presented as means ± SEM. if not indicated otherwise. 
Results 
Experimental procedures and study drugs were generally well 
tolerated, except for Zolpidem, which caused nausea in one sub-
ject. Other common adverse events were mild to moderate seda-
tion and dizziness, which did not affect the capability of the 
subjects to fully comply with the requirements of this study. 
Experiment 1 
Drug effects on SPV 
Repeated-measures ANOVA of drug effects on SPV showed a 
significant main effect of TIME (F(1>19) = 65.52, p < 0.001) and 
DRUG (F(2>38) = 17.22, p < 0.001). In addition, there was a 
significant interaction between TIME and DRUG (F(2>38) = 
16.18,p < 0.001), which was explained by a significant reduction 
of SPV 90 min after intake of alprazolam (p < 0.001) and Zolpi-
dem (p < 0.001), whereas placebo had no significant effect on 
SPV (p > 0.05) (Fig. 2Á). Post hoc analysis further showed that 
reduction of SPV was greater with alprazolam than with Zolpi-
dem (p = 0.018). These results are in line with prior reports 
demonstrating that visually guided SPV is a biomarker of seda-
tion mediated through a l - subuni t -conta in ing GABAARs (de 
Visser et a l , 2003; de Haas et a l , 2009, 2010). This not ion is 
further supported by the degree of modulat ion of SPV (after — 
predrug) by alprazolam and Zolpidem, which showed a signifi-
cant positive correlation (Spearman r 2 = 0.20, p = 0.048; data 
not shown). 
Drug effects on TEPs 
RMT was not significantly different between the predrug condi-
tions (alprazolam: 47.8 ± 1.8% max imum stimulator output 
[MSO]; Zolpidem: 47.4 ± 1.6% MSO; placebo: 48.7 ± 1.9% 
MSO; F (2,38) 1.47, p = 0.24). 
The grand-average TMS-evoked EEG response after single-
pulse TMS of M l at baseline (Fig. 3A) showed the typical TEP 
components (P25, N45, P70, N100, and P180) previously de-
scribed (Lioumis et a l , 2009). Topographical surface voltage 
maps (Fig. 3A) suggested that early TEPs are located in central 
(P25) and contralateral frontal regions (N45). The following 
component (P70) was mainly expressed in the stimulated hemi-
sphere, whereas the later TEPs showed a bilateral distribution 
over central (N100) and centrofrontal sites (P180) (Bonato et a l , 
2006; Ferreri et a l , 2011; Veniero et a l , 2013). 
To determine drug effects on specific TEP components , we 
performed a cluster-based permutat ion analysis of TEP ampli-
tudes in five nonoverlapping TOIs (P25, 20-30 ms; N45, 35-60 
ms; P70, 6 0 - 8 0 ms; N100,85-140 ms; P180,150-230 ms) before 
and after drug intake. Of note, between the predrug conditions, 
there were no significant differences (all TOIs p > 0.005, cor-
rected for multiple comparisons), which may have contributed to 
drug-induced modulat ion of TEPs. The benzodiazepine alprazo-
lam increased the N45 potential (pre: —1.93 ± 0.48 ¡JLV; post: 
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Figure 4. Drug-induced modulation of TEPs. TEPs were recorded before (Pre, blue) and after (Post, red) intake of a single oral 
dose of alprazolam, Zolpidem, or placebo (Experiment 1, A), and diazepam, baclofen, or placebo (Experiment 2, B). Whereas 
alprazolam increased the N45 and reduced the N100amplitude,zolpidem increased the N45 only. Diazepam increased the N45 and 
decreased the N100 similarly to alprazolam, whereas baclofen increased the N100. Black bars underneath represent significant 
drug-induced changes in TEPs. The baseline was corrected between —500 ms and —100 ms. To illustrate drug-induced changes 
of TEP components, representative channels were chosen for each drug condition. Shades represent ± SEM. For further informa-
tion see also Figure 3. 
-3.07 ± 0.68 juiV; p < 0.001) and reduced the N100 (pre: 
-3.91 ± 0.54 ¡LV;post: -2.27 ± 0.36 ¡xV;p < 0.001) (Fig. 4A). In 
contrast, Zolpidem increased the N45 only (pre: —2.68 ± 0.39 
JUV; post: -3.87 ± 0.44 juV;p = 0.001) (Fig. 4A). There were no 
significant differences before versus after placebo in any of the 
five TOIs (p > 0.005, corrected for multiple comparisons) 
(Fig.4A). 
Topographical plots of EEG surface voltages of the drug-
induced changes of the N45 (alprazolam, Fig. 5A; Zolpidem, Fig. 
5C) and N100 (alprazolam, Fig. 55) showed central and right 
hemispheric changes (i.e., changes contralateral to the stimula-
tion site over left Ml hand area). Spearman correlation analysis 
revealed a significant positive correlation between the N45 am-
plitude modulation (postdrug — predrug intake) in the alprazo-
lam and Zolpidem condition (r2 = 0.29,p = 0.014; Fig. 6; average 
of common significant channels F2, FC2, FC4, FC6, FT8, C4, C6, 
T8, CP4, CP6; compare Fig. 5A,C), suggesting activation of al-
containing GABAARs as the common mechanism of action. 
These results were confirmed by a cluster-corrected analysis 
between the postdrug conditions. Compared with placebo, the 
N45 potential under alprazolam and Zol-
pidem was larger (alprazolam vs placebo: 
p = 0.004, significant channels: FT8, Cz, 
C2, C6, T8, CP2, CP4, CP6; Zolpidem vs 
placebo: p < 0.001, significant channels: 
FC2, FC4, FC6, FT8, C2, C4, C6, CPz, 
CP2, CP4, CP6, Pz, P2, P6, POz, P03, 
P04, 02). In addition, the N100 potential 
under alprazolam was smaller compared 
with placebo (p = 0.001, significant chan-
nels: F8, FC2, FC4, FC6, FT8, C2, C4, C6, 
T8, CP4, CP6). Finally, the N100 potential 
under Zolpidem showed a nonsignificant 
trend toward a decrease compared with 
placebo (p > 0.005, corrected for multiple 
comparisons; see Material and Methods). 
In addition, we studied drug-induced 
changes in N45 and N100 potentials at the 
level of individual subjects. Although 
most of the subjects showed increases in 
the N45 potential after intake of alprazo-
lam and Zolpidem (see Fig. 8A) and a re-
duction in the N100 potential after intake 
of alprazolam (see Fig. 85), a few subjects 
had opposite effects compared with the 
group on average. 
To investigate whether drug-induced 
fluctuations in oscillatory neural activ-
ity underlie the observed modulations 
in TEPs, we analyzed EEG power spectra 
at baseline (i.e., —500 to —100 ms be-
fore TMS) predrug/postdrug intake and 
correlated them with drug-induced TEP 
changes. Results showed no significant 
correlations between N45 or N100 am-
plitude modulation and power spectra 
modulation in any of the frequency 
bands analyzed (i.e., 0, a, /3, and y; for 
definition see Material and Methods) by 
alprazolam, or between N45 amplitude 
modulation and 0, a, /3, or y power 
spectra modulation by Zolpidem (all 
p > 0.05), suggesting that TEP changes 
are not based on drug-induced changes in oscillatory neural 
activity. 
Correlation between drug-induced effects on SPV and TEPs 
SPV is a measure of sedation known to be mediated by al-
containing GABAARs (de Visser et al, 2003). Likewise, the above 
data suggested that modulation of the N45 TEP component by 
alprazolam and Zolpidem is mediated by al-containing 
GABAARs. However, we did not find a correlation between 
alprazolam- and zolpidem-induced changes (predrug — post-
drug) of SPV and N45 amplitude (bothp > 0.05). 
Experiment 2 
Drug effects on SPV 
Repeated-measures ANOVA of drug effects on SPV showed a 
significant main effect of TIME (5(1,14) = 15.15, p = 0.002) but 
not of DRUG (5(2,28) = 1-84, p = 0.Í 10), and a significant inter-
action between TIME and DRUG (F(2>28) = 10.17, p < 0.001), 
which was explained by a significant reduction of SPV 90 min 
after intake of diazepam (p = 0.002) (Fig. 25). There was no 
Time (s) 
effect of baclofen or placebo on SPV (both /^ PRE 
p > 0.05). These data confirmed and 
extended the results from Experiment 1 
that reduction of SPV as a biomarker of 
sedation is mediated by al-subunit-
containing GABAARs (de Visser et al, 
2003; de Haas et al, 2009, 2010), whereas 
reduction of SPV is not mediated by 
GABABRs. 
Drug effects on TEPs 
RMT was not significantly different be-
tween the predrug conditions (diazepam: 
44.6 ± 1.3% MSO; baclofen: 44.1 ± 
1.13% MSO; placebo: 44.8 ± 1.18%MSO; 
F(2>28) = 1.12)jP = 0.34). 
The grand-average TMS-evoked EEG 
response after single-pulse TMS of the left 
Ml confirmed the results from Experi-
ment 1, with the most prominent TEP 
components being P25, N45, P70, N100, 
and P180 (Fig. 35). Likewise, topograph-
ical surface voltage maps reproduced that 
early TEPs are located in the stimulated 
sensorimotor cortex (P25) and contralat-
eral regions (N45), whereas late TEPs are 
located in frontocentral sites (Fig. 35). 
As in Experiment 1, a cluster-based 
permutation analysis in the five nonover-
lapping TOIs (P25, 20-37 ms; N45, 
40-60 ms; P70, 65-85 ms; N100, 88-150 
ms; PI80,150-230 ms) showed no signif-
icant difference in TEP amplitudes be-
tween the predrug conditions (all TOIs, 
p > 0.005, corrected for multiple comparisons). Diazepam in-
creased the N45 (pre: -2.19 ± 0.52 juV; post: -3.71 ± 0.54 juV; 
p < 0.001) and reduced the N100 (pre: -3.01 ± 0.41 juV; post: 
-1.07 ± 0.16 ¡xV;p < 0.001) (Fig. 45). In contrast, the GABABR 
agonist baclofen significantly increased the Nl00 (pre: —2.21 ± 
0.34 juV; post: -2.97 ± 0.30 juV;p = 0.003) but had no effect on 
the N45 component (p > 0.005, corrected for multiple compar-
ison) (Fig. 45). In addition, there were no significant differences 
before versus after placebo in any of the five TOIs (p > 0.005, 
corrected for multiple comparisons) (Fig. 45). 
Topographical plots of surface voltages of diazepam-induced 
changes of TEPs showed a right hemispheric modulation of the 
N45 and N100 potentials (i.e., contralateral to the stimulation 
site) (Fig. 7A,5), very similar as observed in the alprazolam con-
dition of Experiment 1 (compare Fig. 5A,5). In contrast, 
baclofen-induced changes in TEPs were predominantly located 
over the left (i.e., stimulated hemisphere) (Fig. 7C). 
These drug-induced effects on TEPs could be confirmed when 
comparing the postdrug TEP amplitudes across drug conditions. 
Compared with placebo, the N45 potential under diazepam was 
larger (p = 0.001, significant channels: FC2, FT8, Cz, C2, C4, C6, 
T8, CP2, CP4, CP6, TP8, P2, P4, P6, P8, P04, P08, 02) and the 
N100 potential under diazepam was smaller (p = 0.002, signifi-
cant channels: FC2, FC4, FC6, FT8, C2, C4, C6, T8, CP4, CP6, 
TP8). The N100 potential under baclofen showed a nonsignifi-
cant trend toward an increase compared with placebo (p = 0.04 
in channels: C3, CI, CP5, CP3, P5, P3, and P03). 
In addition, investigation of drug-induced changes in N45 
and N100 potentials (postdrug/predrug) at the level of individual 
POST 
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Figure 5. lopographical plots for IEP components N45 and Nl 00 before and after intake of alprazolam and Zolpidem (Experi-
ment 1). lopographical distributions of the IEP amplitudes (color coded in /¿V) before (PRE, left column) and after (P0SI, middle 
column) alprazolam (yi,N45;fl,N100) and Zolpidem (C,N45). La rge crosses indicate site of TMSof the hand area of left-hemispheric 
M l . Right column, f-statistic maps of the IEP amplitude postdrug versus predrug differences. Crosses indicate significant channels, 
predominantly in the nonstimulated right hemisphere. Red represents increase in negativity; blue represents decrease in nega-
tivity. For further details, see Material and Methods. 
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Modulation of N45 amplitude by alprazolam (uV) 
Figure 6. Correlation between modulation of the N45 amplitude by alprazolam and Zolpi-
dem (Experiment 1). A significant correlation was found between modulation of the N45 am-
plitude by alprazolam (x-axis) and modulation of the N45 amplitude by Zolpidem (y-axis) 
(Spearman correlation coefficient, r2 = 0.29,p = 0.014). 
subjects showed that most of the subjects showed an increase in 
the N45 potential (Fig. 8C) and a decrease in the N100 potential 
(Fig. 8D) after intake of diazepam, whereas most of the subjects 
showed an increase in the N100 potential after intake of baclofen 
(Fig. 8D). As in Experiment 1, few subjects showed opposite drug 
effects compared with the group on average. 
Importantly, these drug-induced modulations of TEP com-
ponents cannot be explained by drug-induced changes in oscilla-
PRE POST 
N45 Diazepam 
*p< 0.001 
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N100 Diazepam *p< 0.001 
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Figure 7. Topographical plots for TEP components N45 and N100 after intake of baclofen and diazepam (Experiment 2). 
Topographical distributions of the TEP amplitudes (color coded in /¿V) before (PRE, left column) and after (POST, middle column) 
diazepam [A, N45; B, N100) and baclofen (C, N100). Large crosses indicate site of TMS of the hand area of left-hemispheric M l . 
Right column, f-statistic maps of the TEP amplitude postdrug versus predrug differences. Crosses indicate significant channels, 
predominantly in the nonstimulated right hemisphere for diazepam, and in the stimulated left hemisphere for baclofen. Red 
represents increase in negativity; blue represents decrease in negativity. Forfurther details, see Material and Methods. 
tory neural activity, as we did not find any significant correlation 
between diazepam- or baclofen-induced changes in 0, a, /3, or y 
power spectra at baseline (i.e., —500 to —100 ms before TMS) 
predrug/postdrug intake and diazepam- or baclofen-induced 
N45 and N100 amplitude changes, respectively (all p > 0.05). 
These findings thus confirm and extend the results from Experi-
ment 1 that enhancement of neurotransmission through 
GABAARs by diazepam increases early (N45) and decreases late 
(N100) TEP components predominantly in the nonstimulated 
hemisphere, enhancement of neurotransmission through the 
GABABR by baclofen selectively increases the N100 in the stim-
ulated hemisphere. 
Correlation between drug-induced effects on SPV and TEPs 
Similar as for alprazolam in Experiment 1, we did not find a 
significant correlation between diazepam-induced changes of 
SPV and N45 amplitude (p > 0.05). 
Discussion 
Using pharmacological modulation of neurotransmission 
through the GABAAR and GABABR in combination with TMS-
EEG, we show here, for the first time, that activity of al-subunit-
containing GABAARs contributes to early TEPs (the N45 
potential), whereas activity of GABABRs contributes to a later 
TEP (the N100 potential). These findings are discussed in detail 
below. 
The role of GABAARs in TEPs 
A contribution of GABAAergic neurotransmission to TEPs has 
been investigated before in two studies using paired-pulse TMS at 
a short interstimulus interval of 3 ms to 
measure short-interval intracortical inhi-
bition, a marker of GABAAR activity (Zi-
emann et al, 1996). MEP amplitudes were 
•
in line with short-interval intracortical in-
,*r| hibition in both studies, whereas the ef-
7 • ^ec t s °f P a i r ed-Pu l s e TMS on TEPs were 
inconsistent. In one study, paired-pulse 
TMS had no significant effect on the N45 
and N100 amplitudes compared with 
single-pulse TMS (Paus et al, 2001), 
whereas the other study demonstrated a 
focal increase in N45 and N100 ampli-
tudes in the stimulated hemisphere by 
paired-pulse TMS (Ferreri et al , 2011). 
In this study, we applied subtype-
specific modulators at the GABAAR to ex-
plore the contribution of GABAAergic 
neurotransmission on specific TEP com-
ponents. In Experiment 1, the positive 
modulators at the GABAAR alprazolam 
and Zolpidem significantly increased the 
N45 amplitude. Moreover, analysis of 
common channels of significant drug ef-
fects showed that the increase in the N45 
potential in both drug conditions was 
positively correlated, suggesting a com-
mon underlying mechanism. In Experi-
ment 2, we replicated the effect of 
GABAARs on the N45 potential by the 
classical benzodiazepine diazepam. As al-
prazolam, Zolpidem, and diazepam show 
a common receptor profile targeting the 
a 1-subunit of the GABAAR, our data 
strongly suggest that activation of al-subunit-containing 
GABAARs contributes to the generation of the N45 potential. 
Topographical plots of surface voltages of drug-induced 
changes in the N45 potential revealed that these changes were 
predominantly located in the hemisphere contralateral to the site 
of stimulation. In contrast, previous reports showed a dose-
dependent increase in early TEPs at the site of stimulation during 
midazolam-induced loss of consciousness, whereas later TEPs 
were suppressed by midazolam along with a breakdown in corti-
cal effective connectivity (Ferrarelli et al , 2010). This discrepancy 
may be the result of the different sites of stimulation (right pre-
motor cortex in the previous study, left Ml in our study) or the 
level of consciousness (loss of consciousness in the previous 
study, slight sedation in our study). However, comparison be-
tween the two studies is also limited by the fact that topographical 
distributions of surface voltages do not allow to make conclusive 
inferences about the location of changes in the underlying neu-
ronal circuits. To address this issue, source modeling analysis on 
TMS-evoked EEG responses is needed. Whatever the underlying 
mechanism, the topography of drug-induced TEP changes 
matched the topography of the maximum negativity of the N45 
before drug intake (compare right vs left columns in Figs. 5A,C 
and 7A). 
Notably, we did not find a correlation between drug-induced 
changes in our behavioral measure (SPV) and modulation of the 
N45 potential by alprazolam and Zolpidem (Experiment 1) or 
diazepam (Experiment 2). Because the drug-induced changes in 
both measures are mediated by activation of al-subunit-
containing GABAARs, this lack of a correlation suggests a differ-
B 
ent role for GABAAergic neurotrans-
mission in visuomotor processes in spe-
cific frontoparietal networks (i.e., frontal, 
supplementary, and parietal eye fields) 
(Luna et al, 1998) and signal propagation 
of the N45 from left Ml stimulation in a 
widespread distributed cortical network. 
In contrast to the similar effect of al-
prazolam, Zolpidem, and diazepam on the 
N45 amplitude, alprazolam and diaze-
pam, but not Zolpidem, reduced the N100 
amplitude. Topographical plots of surface 
voltages showed that the N100 potential, 
after drug intake, is lateralized to the site 
of stimulation but distributed across 
both hemispheres before drug intake 
(compare Figs. 55 and 75 , C). Drug-
induced changes of the N100 potential 
showed a spatial dissociation: whereas 
the alprazolam- and diazepam-induced 
N100 amplitude decreases were only sig-
nificant in channels in the hemisphere 
contralateral to the stimulation (compare 
Figs. 55 and 75), baclofen-induced N100 
amplitude increases were located in close 
proximity to the stimulation site (com-
pare Fig. 7C). 
The mechanisms of these drug effects 
are not clear. Reduction of the N100 po-
tential in the hemisphere contralateral to 
the stimulation by alprazolam and diaze-
pam, but not Zolpidem, maybe explained 
by a sedation-related suppression of signal propagation from 
the stimulated to the nonstimulated hemisphere (compare 
Figs. 55 and 75). An extensive breakdown of long-range cor-
ticocortical effective connectivity as measured by late TEPs has 
been observed during midazolam-induced loss of conscious-
ness (Ferrarelli et al., 2010) and during NREM sleep (Massi-
miniet a l , 2005). 
Alternatively, propagation of the N100 from the stimulated to 
the nonstimulated hemisphere may involve cortico-subcortical-
cortical loops (e.g., via the thalamus). The thalamus is a major 
subcortical hub and essential for sensory processing and motor 
output (Huguenard and McCormick, 2007). Importantly, 
thalamocortical cells have an excitatory input but are encapsu-
lated by two inhibitory shell-like nuclei: the thalamic reticular 
and perigeniculate nuclei (RT/PGN cells). This sophisticated and 
well-balanced excitatory/inhibitory drive of thalamocortical cells 
is critical for orchestrating thalamocortical oscillations. It is 
known from animal experiments that RT and PGN cells provide 
intrathalamic desynchronizing activity mediated by a3-GABAARs, 
whereas cd-GABAARs located at the level of thalamocortical cells 
are pro-oscillatory (Huguenard and McCormick, 2007). Given 
the higher binding affinity of alprazolam and diazepam than Zol-
pidem to a3-subunit-containing GABAARs, alprazolam/diaze-
pam may favor antioscillatory activity within the thalamocortical 
loop, thus suppressing thalamocortical communication. This 
disruption of thalamocortical connectivity by alprazolam/diaze-
pam may alternatively explain reductions in N100 signal propa-
gation from the stimulated to the nonstimulated hemisphere 
under these conditions. However, further analyses, including 
source modeling, are needed to clarify precisely the propagation 
of TEPs and its change by drugs. 
Alprazolam Zolpidem Placebo Diazepam Baclofen Placebo 
Figure 8. Drug-induced changes of TEPs (single subject data). Scatter plots of individual amplitude modulations (postdrug -
predrug) of the N45 [A, 0 and N100 (B,D) TEP components from Experiments 1 and 2, respectively. The amplitudes were extracted 
for common significant channels in the alprazolam and Zolpidem condition (N45:yi, compare Fig. 5/1,0, significant channels in the 
alprazolam condition (N100:fl, compare Fig. 58), and significant channels in the diazepam condition (N45: C, compare Fig. 7/1).D, 
Data were taken from significant channels in the diazepam and baclofen condition, respectively (as diazepam changed the N100 
contralateral tothestimulation site, whereas baclofen changed the N100 ipsilateral tothe stimulation site; compare Fig.7 8,0- For 
placebo, changes in the N100 were extracted from significant channels in diazepam and baclofen conditions. Error bars indicate 
group mean ± SEM. 
Finally, cellular experiments demonstrated that activation of 
GABAARs inhibits sIPSP generated in neocortical and hip-
pocampal pyramidal neurons by GABABRs (Lopantsev and 
Schwartzkroin, 1999; Thomson and Destexhe, 1999), probably 
through an increase in intracellular chloride concentration that 
inhibits the potassium conductance underlying the GABABR-
mediated sIPSP (Lenz et al, 1997). This maybe another mecha-
nism to account for the observed decrease of the N100 amplitude 
by alprazolam and diazepam. This explanation would fit with the 
observation that diazepam, and lorazepam, another benzodiaz-
epine, resulted in shortening of the cortical silent period duration 
(Inghilleri et al , 1996; Kimiskidis et al, 2006), a TMS-EMG mea-
sure of GABABergic neurotransmission (Siebner et al, 1998). 
The role of GABABR-mediated neurotransmission for TEPs 
The N100 is the most pronounced and reproducible TEP com-
ponent and has been related to sIPSP (Nikulin et al, 2003; Bender 
et al, 2005). Specifically, the N100 amplitude is increased under 
augmented inhibition, such as during preparation to resist a 
forthcoming TMS evoked movement (Bonnard et al, 2009), al-
though it is decreased during preparation to assist a TMS-evoked 
movement (Nikulin et al, 2003), motor response preparation 
(Bender et al, 2005), or motor performance (Kicic et al, 2008). A 
recent study showed that the N100 amplitude is related to the 
duration of the cortical silent period (Farzan et al, 2013). In 
Experiment 2 of our study, baclofen, but not any of the GABAAR 
modulators, increased the N100 amplitude, thus strongly corrobo-
rating a role of GABABRs in the generation of the N100 potential. 
Importantly, none of these drug-induced modulations of TEP 
components can be explained by drug-induced changes in oscil-
latory neural activity (Supp et al, 2011), as we did not find any 
significant correlation between drug-induced changes in 0-, 
[alpha-], j8-, or y-power at baseline (i.e., —500 to —100 ms before 
TMS) and drug-induced N45 and N100 amplitude changes. 
In clinical practice, it would be highly interesting to use TMS-
EEG recordings to study, or even monitor longitudinally, the 
state of neural circuits in individual patients. Previous work in 
healthy subjects showed that TMS-evoked cortical responses es-
sentially reflect deterministic properties of the stimulated net-
work and thus, indeed, may be used to detect longitudinal 
changes in the state of cortical circuits (Casarotto et al, 2010). 
However, our pharmaco-TMS-EEG experiments showed notable 
interindividual variability of drug effects on TEPs, with some 
subjects showing opposite drug effects with respect to the group 
average. Thus, interpretation of TMS-EEG recordings at the 
single-subject level is difficult and maybe limited. Clearly, further 
studies are needed to explore the full potential of TMS-EEG re-
cordings for analysis of perturbation-induced (i.e., drug-, 
training-, noninvasive brain stimulation-, or disease-related) ef-
fects on cerebral networks in individual subjects/patients. 
In conclusion, here we used a novel pharmaco-TMS-EEG 
approach to study the effect of CNS-active drugs directly on 
cortical activity. Our data demonstrate a differential effect of 
GABAAergic versus GABABergic neurotransmission on spe-
cific components of TMS-evoked EEG activity. Findings sug-
gest that TMS-EEG may be used to study GABAAergic and 
GABABergic inhibition in neurological and psychiatric disor-
ders, in which abnormal cortical inhibition has been impli-
cated in the pathophysiology, such as epilepsy or schizophrenia 
(Jones-Davis and Macdonald, 2003; Lewis et al, 2005). In addi-
tion, pharmaco-TMS-EEG offers the opportunity to study the 
actions of CNS-active drugs on human cortex in greater detail 
than it is hitherto possible with TMS or EEG alone. 
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